Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer

Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment

“…As immune cells, T-lymphocytes play an important role in tumor recognition and suppression. In this regard, lymphocyte membrane-camouflaged nanoparticles have also been studied, and shown to exhibit enhanced localization at the tumor site after low-dose irradiation just as is seen with cytotoxic CD8 + T cells 57 .…”

“… Membrane source Cancer model Targeting mechanism Drug-loading Ref. LeukoLike Vectors (LLV) THP-1 and J774 cell line Melanoma Inflammation adhesion None 44 Macrophage cell membrane-camouflaged mesoporous silica nanocapsules (MSNCs) RAW 264.7 4T1 Subcutaneous tumor Unclear DOX 43 Macrophage cell membrane- camouflaged AuNS (MPCM-AuNSs) RAW 264.7 4T1 Subcutaneous tumor Cancer cell recognition Photothermal 47 Macrophage membrane-coated emtansine liposome (MEL) RAW 264.7 4T1 metastasis lung cancer Metastatic cancer cell binding Emtansine 51 Neutrophil mimicking nanoparticles (NM-NPs) Mouse primary neutrophils Circulating tumor cells Metastatic cancer cell binding Carfilzomib 55 Monocyte cell membrane-derived nanoghosts U937 None Cancer cell recognition DOX 56 hCTL membrane-coated PLGA nanoparticles (TPNPs) Human primary T cells Gastric cancer Immune recognition PTX 57 …”

Biomimetic Nanocarriers for Cancer Target Therapy

“…They showed a reduced uptake because of the presence of specific proteins on the RBC membrane, which allowed them to avoid phagocytosis, and increasing circulation time. In another similar recent study [41], biocompatibility assays over PLGA NPs carrying PTX drug, covered with cytotoxic T-lymphocytes membranes for the treatment of gastric cancer showed reduced take by macrophages with respect to the same NPs without hCTL membrane coverage. This result confirmed the property of these biomimetic structures to avoid the immune system.…”

“…Also, they expressed higher levels of adhesion molecules than their naive equivalent cells and were shown to be efficient in targeting the cancer sites. An application of T cell membrane-coated NPs has been described by Zhang and coworkers [41]. This group produced PLGA NPs, loaded with paclitaxel and coated with the membrane of human cytotoxic CD8+ T lymphocytes (hCTLs).…”

Fator de aumento de dose em Radioterapia com nanopartículas: estudo por simulação Monte Carlo

“…Em todos os casos estudados neste trabalho, supôs-se que a radiossensibilização seria dada por processos físicos. O desenvolvimento de radioterapia com nanopartículas, entretanto, tem evoluído, também, na direção do uso de nanopartículas portadoras de quimioterápicos radiossensibilizadores e do desenvolvimento de nanopartículas inteligentes, que deverão ajudar a compor o futuro do diagnóstico e tratamento oncológico (Zang et al, 2017;Kannan et al, 2014).…”